Abstract:Background Hepatocyte growth factor(HGF) can induce non-small cell lung cancer(NSCLC) cells exerting resistance to epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in vitro,suggesting that HGF induced c-Met phosphorylation may be associated with the mechanism of erlotinib resistance in sensitive NSCLC.Objective The study aimed to demonstrate that c-Met inhibitor SU11274 can reverse the erlotinib resistance induced by HGF in sensitive NSCLC cells in nude mice.Methods This study was conducted from March 2014 to January 2015.Two cell lines including H292 and human embryonic fibroblast MRC-5 were chosen.The HGF produced by MRC-5 cells in cell culture supernatants was quantitated by enzyme-linked immunosorbent assay(ELISA).The proliferation of H292 cells was measured by using MTT assay and the expressions of c-Met and its downstream signaling proteins were examined by Western blotting.We selected forty-nine 6-week old nude mice and equally divided them into 7 groups,group C (control group),group H,group HS,group HD,group E,group HE,group HES,treated with H292 cell suspension,HGF,HGF+SU11274,HGF+1% DMSO,erlotinib,HGF+erlotinib,HGF+erlotinib+SU11274,respectively.The tumor growth was observed and the growth curve was drawn.The tumor weight was recorded.The expressions of c-Met and downstream signaling proteins in tumor tissues were determined via immunohistochemistry.Results ELISA assay found that the HGF level in the culture supernatant of MRC-5 cells was (1 262±90) pg/ml.MTT assay showed that in the mixture of H292 and MRC-5 cells culture supernatant with erlotinib concentration of IC50,the proliferation of H292 cells was 97.07%.The expressions of p-Met,p-STAT3,p-AKT and p-ERK1/2 in the culture supernatant of H292 with MRC-5 cells were higher than those in the H292 cell culture supernatant(P<0.05).Intervention method and duration exerted significant interaction effects on the tumor volume(P<0.001).Intervention method produced main effect on the tumor volume(P<0.001).Intervention duration had main effect on the tumor volume(P<0.001).The tumor volume was smaller in HES group than in HE group measured on the 7th,11th,14th,18th,21st and 25th days of intervention (P<0.05).The tumor mass differed significantly between the groups(F=39.120,P<0.001).HES group had less tumor mass than HE group did(P<0.05).Significant differences in the expressions of c-Met,p-Met,p-STAT3,p-AKT and p-ERK1/2 were found between the groups(P<0.05).The expressions of c-Met,p-Met,and p-STAT3 proteins were lower in HES group than those in HE group(P<0.05).Conclusion HGF secreted by MRC-5 induces erlotinib resistance in H292 cells in nude mice.c-Met inhibitor SU11274 reverses the resistance of HGF-induced sensitive NSCLC cells to erlotinib in vivo.The mechanism may be related to the inhibition of HGF-induced activation of c-Met and its signaling pathway proteins.

Mechanism of SU11274 Reversing the Resistance to Erlotinib Induced by Hepatocyte Growth Factor in Non-small Cell Lung Cancer Cells

The Mechanism of Gefitinib Resistance Induced by Hepatocyte Growth Factor in Sensitive Non-small Cell Lung Cancer Cells in Vitro

SU11274 reverse geiftinib resistance induced by hepatocyte growth factor in differentEGFR gene type of non-small cell lung cancer cells

MicroRNA-34a Overcomes HGF-mediated Gefitinib Resistance in EGFR Mutant Lung Cancer Cells Partly by Targeting MET.

Hepatocyte Growth Factor As Inducer of Gefitinib Resistance in Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib As 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Beta 1 Integrin Mediated Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Lung Cancer Cells

Inhibitory effect and mechanism of gefitinib combined with metformin on EGFR-TKI intrinsic resistant NSCLC H1975 cells

Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.

Ehf Enhances Malignancy By Modulating Akt And Mapk/Erk Signaling In Non-Small Cell Lung Cancer Cells

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.

Suppression of C-Met Overcomes Erlotinib Resistance in Tongue Cancer Cells

Specific Growth Inhibition by Alteration of Metabolic Pathway Using Chinese Herbal Medicine in Tyrosine Kinase Inhibitor Resistant Non-Small Cell Lung Cancer

Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines

Methylseleninic Acid Overcomes Gefitinib Resistance Through Asparagine-Met-topk Signaling Axis in Non-Small Cell Lung Cancer Cells.

HDGF Promotes Gefitinib Resistance by Activating the PI3K/AKT and MEK/ERK Signaling Pathways in Non-Small Cell Lung Cancer

Ezh2 Inhibitors Reverse Resistance to Gefitinib in Primary Egfr Wild-type Lung Cancer Cells